



# Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review

## Citation

Roberson, L. L., E. C. Aneni, W. Maziak, A. Agatston, T. Feldman, M. Rouseff, T. Tran, et al. 2014. “Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review.” BMC Public Health 14 (1): 14. doi:10.1186/1471-2458-14-14. <http://dx.doi.org/10.1186/1471-2458-14-14>.

## Published Version

doi:10.1186/1471-2458-14-14

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879602>

## Terms of Use

This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

RESEARCH ARTICLE

Open Access

# Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review

Lara L Roberson<sup>1</sup>, Ehimen C Aneni<sup>1</sup>, Wasim Maziak<sup>3</sup>, Arthur Agatston<sup>1</sup>, Theodore Feldman<sup>1</sup>, Maribeth Rouseff<sup>2</sup>, Thinh Tran<sup>2</sup>, Michael J Blaha<sup>4</sup>, Raul D Santos<sup>5</sup>, Andrei Sposito<sup>6</sup>, Mouaz H Al-Mallah<sup>7</sup>, Ron Blankstein<sup>8</sup>, Matthew J Budoff<sup>9</sup> and Khurram Nasir<sup>1,3,4,10\*</sup>

## Abstract

**Background:** A subgroup has emerged within the obese that do not display the typical metabolic disorders associated with obesity and are hypothesized to have lower risk of complications. The purpose of this review was to analyze the literature which has examined the burden of cardiovascular disease (CVD) and all-cause mortality in the metabolically healthy obese (MHO) population.

**Methods:** Pubmed, Cochrane Library, and Web of Science were searched from their inception until December 2012. Studies were included which clearly defined the MHO group (using either insulin sensitivity and/or components of metabolic syndrome AND obesity) and its association with either all cause mortality, CVD mortality, incident CVD, and/or subclinical CVD.

**Results:** A total of 20 studies were identified; 15 cohort and 5 cross-sectional. Eight studies used the NCEP Adult Treatment Panel III definition of metabolic syndrome to define “metabolically healthy”, while another nine used insulin resistance. Seven studies assessed all-cause mortality, seven assessed CVD mortality, and nine assessed incident CVD. MHO was found to be significantly associated with all-cause mortality in two studies (30%), CVD mortality in one study (14%), and incident CVD in three studies (33%). Of the six studies which examined subclinical disease, four (67%) showed significantly higher mean common carotid artery intima media thickness (CCA-IMT), coronary artery calcium (CAC), or other subclinical CVD markers in the MHO as compared to their MHNW counterparts.

**Conclusions:** MHO is an important, emerging phenotype with a CVD risk between healthy, normal weight and unhealthy, obese individuals. Successful work towards a universally accepted definition of MHO would improve (and simplify) future studies and aid inter-study comparisons. Usefulness of a definition inclusive of insulin sensitivity and stricter criteria for metabolic syndrome components as well as the potential addition of markers of fatty liver and inflammation should be explored. Clinicians should be hesitant to reassure patients that the metabolically benign phenotype is safe, as increased risk cardiovascular disease and death have been shown.

\* Correspondence: [Khurramn@baptisthealth.net](mailto:Khurramn@baptisthealth.net)

<sup>1</sup>Center for Prevention and Wellness Research, Baptist Health Medical Group, Michigan Ave Suite 500, Miami Beach, Florida

<sup>3</sup>Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida

Full list of author information is available at the end of the article

## Background

It is well established that obesity continues to rise in prevalence, nearly doubling between the years of 1980 and 2008 worldwide [1]. In the United States between 2009–2010, the rate of obesity was 35.7% in adults and 17% in children [2], which translates into about 78 million adults and 12.5 million children. In literature review, obesity has been shown to be predictive of all-cause, cardiovascular disease (CVD), and cancer mortality [3,4]. Economically, obesity is costly due to its direct association with morbidity and mortality, with the medical costs of treating obesity and its sequelae estimated to be \$147 billion in 2009 [5]. From a clinical perspective, the question remains how to best identify those who are at the lowest risk of developing these obesity-related complications, and monitor them in a cost effective way, while allocating the most resources to those in the highest risk group.

A subgroup has been identified within the obese population, who do not display the typical metabolic disorders associated with obesity and are hypothesized to have lower risk of obesity-related complications. Metabolically healthy obesity (MHO), as it will be referred to in this review, has been previously defined as a subgroup of obese individuals who do not have insulin resistance, lipid disorders, or hypertension [6]. Multiple studies indicate 10-25% of the obese can be categorized as MHO [6,7]. Wildman et al. used NHANES, a nationally representative sample of adults living in the US, to examine the MHO phenotype and found a prevalence of 32% among obese adults over the age of 20 [8].

In this review, we aim to evaluate the MHO phenotype in context of cardiovascular disease risk and all-cause mortality. By conducting a systematic literature search which selected studies assessing the association of the MHO phenotype with all-cause mortality, CVD outcomes and subclinical CVD, we sought to summarize the risks in this group, and discuss the challenges faced by studies in examining this unique population.

## Methods

A systematic literature search was conducted using Pubmed, Web of Science, and Cochrane Library. In Pubmed, the following medical subject headings (MESH) and free text terms were used: (“metabolically healthy” OR “metabolically normal” OR “metabolically benign” OR “insulin sensitive”) AND (“obese” OR “overweight”). The same text word search was used in Web of Science and Cochrane Library as in Pubmed. No restrictions were used for publication status or date, but studies had to be peer-reviewed to be selected. Libraries were searched until December 2012. Studies were selected if they were written in English, included human subjects over the age of 18, defined a metabolically healthy obese/overweight group and contained either a measure of subclinical cardiovascular

disease or a hard outcome such as death or cardiovascular disease. Studies were excluded if they failed to include a comparison group to the MHO, the abstract and full text was unavailable, or were reviews, letters, and case-reports. Studies were also excluded if they failed to define metabolically healthy using either insulin sensitivity or components of metabolic syndrome or failed to define obesity using BMI, body fat percentage, or waist circumference. Two reviewers independently selected articles, and then jointly agreed on the final studies to be included.

## Results

### Eligible studies


Our search identified a total of 340 studies from Pubmed, 156 from Web of Science, and 20 from Cochrane library. Six more studies were identified by searching the reference lists of all full-text papers included from the initial database search. Twenty articles met the final inclusion criteria (Figure 1).

### Cohort studies

A total of 14 cohort studies were identified which examined the MHO phenotype and mortality or cardiovascular outcomes [9-22] (Tables 1 and 2). These studies reported an average follow-up time of 11 years. In total, the 14 studies examined 359,137 participants, 9,865 fitting the MHO phenotype, or 2.7% of the total population studied. One study examined the MHO phenotype and progression of subclinical cardiovascular disease at three-year follow-up [23]. The majority of studies examined risks in Caucasian subjects or subjects of European descent ( $n = 12$ ). One study used an Iranian cohort [12] and one study did not report ethnicity [13]. On average, participants were over the age of 50 ( $n = 9$ ), while a small segment of studies reported younger average age ( $n = 4$ ), or did not report age [13]. One cohort study examined the MHO phenotype and subclinical CVD [23] (Tables 3 and 4).

### *i. Definitions of MHO*

Studies were examined in reference to their definition of MHO (Table 1). In 13 of the studies, obesity was defined as  $BMI \geq 30 \text{ kg/m}^2$ . The remaining study defined obesity as either  $BMI \geq 30 \text{ kg/m}^2$  or body fat  $> 25\%$  in men and  $30\%$  in women [16]. Three studies included measures of inflammation (either C-Reactive protein [CRP] or white blood cell [WBC] count) in the definition of MHO [11,15,17]. Two studies defined “metabolically healthy” as absence of metabolic syndrome (MetS) based on the NCEP ATP III definition of MetS without any modification [18,19]. Five studies defined “metabolically healthy” as absence of MetS with study specific modifications to the MetS criteria [11,12,16,20,21]. One study used only insulin sensitivity (IS) to define “metabolically healthy” [10]. Two studies created a unique definition using a combination of



insulin sensitivity (IS) and MetS [17,23]. Lastly, four studies examined both the IS and MetS definitions of “metabolically healthy” within the same study [9,13-15].

## ii. Outcomes measured

- a. *All-cause mortality.* Seven studies reported all-cause mortality [9-11,13,16,19,23]. MHO was found to be significantly associated with all-cause mortality in two studies (30% of studies). Five studies used metabolically healthy, normal weight (MHNW) as the comparison group [9,13,16,19,23] of which the two significant studies were included. Two used metabolically normal, “not obese, BMI <30 kg/m<sup>2</sup>” [10,11] as the comparison and both reported null results. Finally, four studies controlled for physical fitness (either reported exercise or measured cardio-respiratory fitness) of which all reported null results [11,16,19,24].
- b. *CVD mortality.* Seven studies separately analyzed CVD mortality [9-11,16,19,20,23]. Five studies showed no statistically significant association between MHO and CVD mortality, but pointed towards higher CVD mortality in the MHO [9,11,16,19,20]. Only one study (14% of reviewed studies) found the metabolically healthy obese to have significantly higher risk of CVD mortality [23]. The studies using “metabolically normal, not obese” rather than “normal weight” as their comparison group found no association between MHO and CVD mortality [10,11].
- c. *Incident CVD.* Nine studies examined incident CVD events [9,12,14-19,21,23]. Incident CVD was defined as stroke, coronary heart disease (CHD), and/or heart failure. Three studies (33%) reported significant increase in risk of CVD events among the MHO [9,15,23]. Five studies showed no statistically significant association between incident CVD and MHO, but consistently pointed towards an incidence of CVD in the MHO approximately 1.5 times that of the comparison group [11,12,14,17,21]. The single study which was non-significant and did not point towards an increase in risk had a follow up of 6 years, small sample size of 550, and measured only incident heart failure [18].
- d. *Subclinical measures of CVD.* Bobbioni-Harsch et al. examined the three year progression of common carotid intima medial thickness (CCA-IMT), a measure of arterial wall thickness and indicator of atherosclerotic disease progression, in a cohort of

**Table 1 MHO definition; cohort studies**

Study	Definition of metabolically healthy obese (MHO)	Definition of metabolically healthy, normal weight (MHNW)
Katzmarzyk [19]	<ul style="list-style-type: none"> <li>• &lt;3 MetS</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• <math>\leq 2</math> MetS criteria, normal weight (BMI 18.5-24.9 kg/m<sup>2</sup>)</li> </ul>
St-Pierre [17]	<ul style="list-style-type: none"> <li>• <math>\leq 2</math> insulin resistance syndrome<sup>A</sup> (IRS) criteria</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics excluded</li> </ul>	<ul style="list-style-type: none"> <li>• <math>\leq 2</math> IRS<sup>A</sup> criteria, normal weight (BMI &lt;25 kg/m<sup>2</sup>)</li> </ul>
Meigs [14]	<ul style="list-style-type: none"> <li>• &lt;3 MetS criteria and/or IS by HOMA-IR &lt; 75th percentile</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics excluded</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;3 MetS criteria, normal weight (BMI &lt; 25 kg/m<sup>2</sup>) and/or IS, normal weight (BMI &lt; 25 kg/m<sup>2</sup>)</li> </ul>
Daly [20]	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>B</sup></li> <li>• BMI &gt; 30 kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>B</sup>, normal weight (BMI &lt;25 kg/m<sup>2</sup>)</li> </ul>
Song [21]	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>C</sup> criteria</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>C</sup>, normal weight (BMI &lt;25 kg/m<sup>2</sup>)</li> </ul>
Kuk [13]	<ul style="list-style-type: none"> <li>• <math>\leq 1</math> MetS criteria and/or IS by HOMA &lt; 2.5</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• <math>\leq 1</math> MetS criteria, normal weight (BMI &lt; 25 kg/m<sup>2</sup>) and/or IS, normal weight (BMI &lt; 25 kg/m<sup>2</sup>)</li> </ul>
Arnlov [9]	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>D</sup> criteria and/or IS by HOMA-IR &lt;75th percentile</li> <li>• BMI &gt; 30 kg/m<sup>2</sup></li> <li>• Diabetics excluded</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>D</sup> criteria, normal weight (BMI &lt; 25 kg/m<sup>2</sup>) and/or IS, normal weight (BMI &lt; 25 kg/m<sup>2</sup>)</li> </ul>
Calori [10]	<ul style="list-style-type: none"> <li>• IS by HOMA-IR &lt; 2.5</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• IS, not obese (BMI &lt; 30 kg/m<sup>2</sup>)</li> </ul>
Voulgari [18]	<ul style="list-style-type: none"> <li>• &lt;3 MetS criteria</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics excluded</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;3 MetS criteria, normal weight (BMI &lt;24.9 kg/m<sup>2</sup>)</li> </ul>
Hosseinpah [12]	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>E</sup> criteria</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;3 MetS<sup>E</sup> criteria, normal weight (BMI 18.5-24.9 kg/m<sup>2</sup>)</li> </ul>
Bobbioni-Harsch [23]	<ul style="list-style-type: none"> <li>• 0 MetS criteria</li> <li>• BMI <math>\geq 25</math> kg/m<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>• 0 MetS criteria, normal weight (BMI &lt; 25 kg/m<sup>2</sup>)</li> </ul>
Ogorodnikova [15]	<ul style="list-style-type: none"> <li>• <math>\leq 2</math> MetS<sup>C</sup> criteria; <math>\leq 1</math> of any MetS<sup>C</sup> criteria, IR by HOMA-IR &gt; 75th percentile of all participants, or systemic inflammation by WBC &gt;75th percentile for all participants; or IS by HOMA-IR <math>\leq 25</math>th percentile among non-diabetic obese, sex-specific</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• <math>\leq 2</math> MetS<sup>C</sup> criteria, normal weight (BMI 18.5-24.9 kg/m<sup>2</sup>) or <math>\leq 1</math> MetS<sup>C</sup> criteria, IR by HOMA-IR &gt; 75th percentile of all participants, or systemic inflammation by WBC &gt;75th percentile for all participants, normal weight (BMI 18.5-24.9 kg/m<sup>2</sup>) or IS, normal weight (BMI 18.5-24.9 kg/m<sup>2</sup>)</li> </ul>
Hamer [11]	<ul style="list-style-type: none"> <li>• &lt;2 MetS<sup>F</sup> criteria (including CRP <math>\geq 3.0</math> mg/L)</li> <li>• BMI <math>\geq 30</math> kg/m<sup>2</sup> or waist circumference &gt;102 cm men, &gt;88 cm women</li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• &lt;2 MetS<sup>F</sup> criteria, not obese (BMI 18–29.9 kg/m<sup>2</sup>) or &lt;2 MetS<sup>F</sup> criteria, normal waist (<math>\leq 102</math> cm in men, <math>\leq 88</math> cm in women)</li> </ul>

**Table 1 MHO definition; cohort studies (Continued)**

Bo [22]	<ul style="list-style-type: none"> <li>• &lt; IS by HOMA &lt; 2.5 AND &lt; 3 MetS<sup>G</sup> criteria</li> <li>• BMI &gt; 30 kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• IS, normal weight (BMI &lt; 25 kg/m<sup>2</sup>)</li> </ul>
Ortega [16]	<ul style="list-style-type: none"> <li>• ≤ 1 MetS<sup>C</sup> criteria</li> <li>• Body Fat% ≥ 25/30 (M/F) OR BMI ≥ 30 kg/m<sup>2</sup></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• ≤ 1 MetS<sup>C</sup> criteria, normal weight (BMI 18.5-24.9 kg/m<sup>2</sup>) or • ≤ 1 MetS<sup>C</sup> criteria, normal body fat (&lt; 25% men/&lt; 30% women)</li> </ul>

<sup>A</sup>TG ≥ 150 mg/dL, HDL < 50 mg/dL, ≥ 54.5% of LDL particles with diameter < 255A, Apo lipoprotein B level ≥ 1.36 g/L, fasting insulin level ≥ 85.2 pmol/L, blood pressure ≥ 135/85 mmHg, CRP ≥ 3.0 mg/L; <sup>B</sup>TG and waist circumference excluded, added BMI > 30 kg/m<sup>2</sup> into criteria; <sup>C</sup>Waist circumference excluded; <sup>D</sup>Waist circumference excluded, added BMI ≥ 29.4 kg/m<sup>2</sup> cut-point into criteria; <sup>E</sup>Waist circumference ≥ 89 cm for men and ≥ 91 cm for women, blood pressure ≥ 140/85 mmHg; <sup>F</sup>TG excluded, added CRP ≥ 3 mg/L into criteria; <sup>G</sup>Waist circumference ≥ 94 cm for men and ≥ 80 cm for women, fasting plasma glucose ≥ 100 mg/dl or use of hypoglycemic therapy.

376 metabolically healthy adults aged 30 to 60 years [23] (Tables 1 and 2). At baseline and three years, cardio-metabolic risk factors were measured. Participants were grouped by weight class and according to their metabolic status at follow up. They were considered at-risk if they had developed one or more cardio-metabolic risk factors. At baseline, there was no significant difference in mean CCA-IMT between weight classes. Among the metabolically normal at follow-up, mean CCA-IMT was significantly higher in obese women as compared to normal body weight women. In regression, BMI was significantly associated with the occurrence of ≥ 1 cardio-metabolic risk factors in all subgroups at follow-up. The incidence of one or more cardio-metabolic risk factors was 57.2% in overweight and obese participants who were metabolically normal at baseline, compared with 31.7% of normal weight participants. Also, they found independent of metabolic abnormalities, the CCA-IMT was thicker in the obese and overweight, than in the normal weight.

### iii. Other considerations

- Inflammation.** A total of 5 of the 14 included studies reported any measure of inflammation. Four studies documented C-reactive protein (CRP) levels [11,17,21,22]. One study used white blood cell count > 75<sup>th</sup> percentile as a marker of inflammation [15]. Hamer, Ogorodokniva and St Pierre included vascular inflammation in the definition of metabolic health [11,15,17]. Only one study adjusted for the presence of vascular inflammation in predicting CVD [21]. None of these studies reported the association of vascular inflammation with CVD outcomes.
- Risk-reducing behaviors.** Eight of 14 studies included measures of exercise or fitness [11-13,16,18,19,21,23]. One study measured cardio-respiratory fitness by treadmill test and found that increased physical activity offset the increased CVD mortality seen in the MHO [19]. Seven studies utilized self-reported measures of physical activity and

found that the MHO had higher physical activity levels as compared to the MUHO. However, these studies did not assess the effect of physical activity alone on CVD outcomes in the metabolically healthy obese. Only three studies documented dietary behaviors in the study populations [13,21,23]. All three utilized self reported methods. Out of these, one study found that in subjects with BMI < 30, insulin sensitive individuals had significantly higher mean daily fiber consumption as compared to insulin resistant subjects. No significant difference was found in fiber consumption between insulin sensitive or resistant subjects with BMI > 30 [23].

### Cross sectional studies

A total of five cross sectional studies met inclusion criteria, [25-29] (Tables 3 and 4). In total 5,234 participants were examined for prevalence of subclinical CVD in relation to the MHO phenotype.

#### i. Definitions of MHO

All studies included diabetics. Two studies defined obese/overweight as BMI ≥ 25 kg/m<sup>2</sup> [27,28]. The remaining studies used BMI > or ≥ 30 kg/m<sup>2</sup>. Two studies defined MHO using IS [25,26]. Of the remaining three studies, one used the standard NCEP ATP III definition of MetS [29], and the other two used a modified version of the MetS definition [27,28]. One study included CRP < 3 mg/L in the definition of “metabolically healthy” [27].

#### ii Outcomes measured

- Common carotid artery-intima medial thickness.** All five of the studies measured CCA-IMT as a marker of atherosclerosis. Of the four studies reporting mean difference in CCA-IMT between MHO and MHNW individuals [25-28], two reported significantly higher levels in the MHO [25,27]. However, in the two studies that did not attain statistical significance, the mean CCA-IMT tended to be higher in the MHO group as compared to the

**Table 2 Results; cohort studies**

Study	Subjects (age, male)	Median follow-up time (yrs)	Outcome	Results
Katzmarzyk [19]	N = 19,173  MHO = 1,019 (43, 100%)  MHNW = 7,153 (41, 100%)	10	All-cause mortality CVD mortality	MHO = All cause: 25 (3%); CVD: 12 (1%); MHNW = All-cause: 160 (2%); CVD: 38 (1%);  •Unadjusted HR for MHO vs. MHNW = NR (All-cause); NR (CVD)  •Adjusted <sup>A</sup> HR for MHO vs. MHNW = 0.88 (0.57-1.36) [All-cause]; 1.59 (0.81-3.12) [CVD]
St-Pierre [17]	N = 1,824  MHO = 54 (NR, 100%)  MHNW = 512 (NR, 100%)	13	Incident CVD	Total = 284 (16%); MHO = NR; MHNW = NR  •Unadjusted HR for MHO vs. MHNW = NR  •Adjusted <sup>B</sup> HR for MHO vs. MHNW = 1.53 (0.79-3.00)
Meigs [14]	N = 2,902  MHO = 236 (52, 51%)  MHNW = 981 (52, 27%)	11	Incident CVD	MHO = CVD: 19 (8%); MHNW = CVD: 19 (5%);  •Unadjusted RR for MHO vs. MHNW = NR  • Adjusted <sup>C</sup> RR for MHO (MetS) vs. MHNW = 1.48 (0.87-2.55)[CVD]  •Adjusted <sup>C</sup> RR for MHO (IS) vs. MHNW = 1.42 (0.87-2.33) [CVD]
Daly [20]	N = 8,397 (60, 87%)  MHO = 839 (NR,NR)  MHNW = NR	4	CVD mortality	MHO = NR (3%); MHNW = NR (2%)  •Unadjusted RR for MHO vs. MHNW = 1.42 (0.76-2.63)  •Adjusted RR for MHO vs. MHNW = NR
Song [21]	N = 25,626  MHO = 2,925 (54, 0%)  MHNW = 12,943 (54, 0%)	10	Incident CVD	MHO = CVD: 77 (3%); MHNW = CVD: 278 (2%)  •Unadjusted RR for MHO vs. MHNW = NR  •Adjusted <sup>D</sup> RR for MHO vs. MHNW = 1.05 (0.66-1.66)  •Adjusted <sup>E</sup> RR for MHO vs. MHNW = 1.07 (0.68-1.70)
Kuk [13]	N = 6,011  MHO = 78 (NR, NR)  MHNW = 1,461 (NR, NR)	9	All-cause mortality	Total = 292 (5%); MHO = NR; MHNW = NR  •Unadjusted RR for MHO (MetS) vs. MHNW = NR  •Adjusted <sup>F</sup> RR for MHO (MetS) vs. MHNW = <b>2.80 (1.18-6.65)</b>  •Unadjusted RR for MHO (IS) vs. MHNW = NR  •Adjusted <sup>F</sup> RR for MHO (IS) vs. MHNW = <b>2.58 (1.00-6.65)</b>
Arnlov [9]	N = 1,758  MHO = 30 (50, 100%)  MHNW = 891 (50, 100%)	30	All-cause mortality  CVD mortality  Incident CVD	MHO = All-cause: 18 (60%); CVD mortality: 5 (17%) MHNW = All-cause: 391 (44%); CVD mortality: 155 (17%)  •Unadjusted RR for MHO (MetS) vs. MHNW = NR  • Adjusted <sup>G</sup> RR for MHO (MetS) vs. MHNW = <b>1.65 (1.03-2.66)</b> [All-cause]; 1.20 (0.49-2.93) [CVD mortality]; <b>1.95 (1.14-3.34)</b> [Incident CVD]  • Adjusted <sup>G</sup> RR for MHO (IS) vs. MHNW = <b>2.04 (1.25-3.32)</b> [All-cause]; 1.80 (0.79-4.08) [CVD mortality]; <b>1.91 (1.07-3.41)</b> [Incident CVD]
Calori [10]	N = 2,011  MHO = 43 (55, 28%)  MHNW = 708 (55, 45%)	15	All-cause mortality  CVD mortality	MHO = All-cause: 7 (16%); CVD: 2 (5%) MHNW = All-cause: 141 (20%); CVD: 58 (8%)  •Unadjusted HR for MHO vs. MHNW = NR  •Adjusted <sup>H</sup> HR for MHO vs. MHNW = 0.99 (0.46-2.11) [All-cause]; 0.73 (0.18-3.00) [CVD]
Voulgari [18]	N = 550 (60, NR)  MHO = 96 (NR, NR)  MHNW = 109 (NR, NR)	6	Incident heart failure	MHO = 43 (9%); MHNW = 17 (16%)  •Unadjusted HR for MHO vs. MHNW = 0.26 (NR)  •Adjusted <sup>I</sup> HR for MHO vs. MHNW = 0.41 (0.10-1.31)

**Table 2 Results; cohort studies (Continued)**

Hosseinpanah [12]	N = 6,215 MHO = 408 (45, 20%) MHNW = 1,555 (45, 57%)	8	Incident CVD	MHO = 13 (3%); MHNW = 64 (4%) •Unadjusted HR for MHO vs. MHNW = NR •Adjusted <sup>J</sup> HR for MHO vs. MHNW = 1.07 (0.59-1.96)
Bobbioni Harsch [23]	N = 436 MHO = 65 (45, 42%) MHNW = 194 (43, 23%)	3	CCA-IMT	Male Subjects <i>Mean CCA-IMT at Baseline</i> : MHO = 0.63 (0.07) vs. MHNW = 0.59 (0.08) p = NS <i>Mean CCA-IMT at 3 years</i> : MHO = 0.62 (0.10) vs. MHNW = 0.60 (0.07) p = NS Female Subjects <i>Mean CCA-IMT at Baseline</i> : MHO = 0.57 (0.06) vs. MHNW = 0.56 (0.06) p = NS <i>Mean CCA-IMT at 3 years</i> : MHO = 0.61 (0.08) vs. MHNW = 0.58 (0.06) <b>p &lt; 0.05</b>
Ogorodnikova [15]	N = 17,544 MHO = 1,167 (56, 32%) MHNW = 4,036 (58, 33%)	12	Incident CVD	Total = 2,439 (14%); MHO = NR; MHNW = NR •Unadjusted HR for MHO vs. MHNW = NR •Adjusted <sup>K</sup> HR for MHO (using various definitions) vs. MHNW = <b>1.30 (1.03-1.66)</b> [ATP III definition]; 1.17 (0.87-1.57) [ATP-III Expanded]; <b>1.52 (1.19-1.95)</b> [IS definition]
Hamer [11]	N = 22,203 MHO = 1,160 (51.3, 53%) MHNW = 12,716 (51.9, 45%)	7	All-cause mortality CVD mortality	MHO = All-cause: 38 (3%); CVD: 18 (2%); MHNW = All-cause: 777 (6%); CVD: 225 (2%) •Unadjusted HR for MHO vs. MHNW = NR •Adjusted <sup>L</sup> HR for MHO v. MHNW = 0.91 (0.64-1.29) [All-cause]; 1.26 (0.74-2.13) [CVD]
Bo [22]	N = 1,658 MHO = 72 (55, 33%) MHNW = 540 (54, 38%)	9	All-cause mortality CVD mortality Incident CVD	MHO = All-cause: 15 (21%); CVD mortality: 8 (11%); Incident CVD: NR (8%) MHNW = All-cause: 28 (5%); CVD mortality: 7 (1%); Incident CVD: NR (3%) •Unadjusted HR for MHO vs. MHNW = NR •Adjusted <sup>M</sup> HR for MHO vs. MHNW = 1.36 (0.64-2.08) [All-cause]; <b>2.48(1.35-3.61)</b> [CVD mortality]; <b>2.76 (1.05-7.28)</b> [Incident CVD]
Ortega [16]	N = 43,265 MHO = 1,738 (NR, 80%) MHNW = 16,002 (NR,NR)	14	All-cause mortality CVD mortality Incident CVD	MHO = All-cause: 52 (3%); CVD mortality: 17 (1%); Incident CVD: 30 (6%) MHNW = All-cause: 449 (3%); CVD mortality: 98 (1%); Incident CVD: 261 (4%) •Unadjusted HR for MHO(referent) vs. MHNW = NR •Adjusted <sup>N</sup> HR for MHO(referent) vs. MHNW = 0.91 (0.67-1.24) [All-cause]; 0.73 (0.42-1.28) [CVD mortality]; 0.78 (0.52-1.18) [Incident CVD]

<sup>A</sup>Adjusted for age, year of exam, smoking, alcohol use, possible existence of CVD, parental history or premature CVD, cardio-respiratory fitness; <sup>B</sup>Adjusted for age, smoking, and medication use at baseline; <sup>C</sup>Adjusted for age, sex, LDL, smoking; <sup>D</sup>Adjusted for age, treatment assignment, smoking, exercise, alcohol use, total calorie intake, postmenopausal hormone use, multivitamin use, parental history of myocardial infarction before 60 years, BMI; <sup>E</sup>Adjusted for age, treatment assignment, smoking, exercise, alcohol use, total calorie intake, postmenopausal hormone use, multivitamin use, parental history of myocardial infarction before 60 years, CRP; <sup>F</sup>Adjusted for age, sex, income, smoking, ethnicity, alcohol use; <sup>G</sup>Adjusted for age, smoking, and LDL; <sup>H</sup>Adjusted for age, sex; <sup>I</sup>Adjusted for age, sex, impaired glucose tolerance, dyslipidemia, hypertension, smoking, physical inactivity, left ventricular hypertrophy, and function on echocardiography; <sup>J</sup>Adjusted for age, gender, exercise, smoking, family history of premature CAD, high total cholesterol; <sup>K</sup>Adjusted for age, gender, race, smoking, education, alcohol use, and study cohort; <sup>L</sup>Adjusted for age, sex, smoking physical activity, socioeconomic group, and BMI; <sup>M</sup>Adjusted for age, sex, fiber intake, exercise, waist circumference; <sup>N</sup>Adjusted for age, sex, examination year, smoking, alcohol, parental history of CVD, fitness.

MHNW group [26,28]. The final study determined that carotid atherosclerosis was similar among normal weight, overweight, and obese participants when stratified by presence or absence of MetS,

- b. *Other subclinical measures of CVD*. One study assessed coronary artery calcium (CAC), which is an early indicator of atherosclerotic disease measuring

the degree of calcification in the coronary arteries [27]. Khan et al. reported higher mean levels of CAC and increased frequency of higher CAC in the metabolically healthy obese as compared to controls. One study assessed liver fat, and found that the frequency of MHO participants with fatty liver was significantly higher than that of normal weight, but



**Table 3 MHO Definition; Cross Sectional Studies**

Study	Definition of metabolically healthy obese (MHO)	Definition of metabolically healthy, normal weight (MHNW)
Marini [25]	<ul style="list-style-type: none"> <li>• IS by OGTT &amp; euglycemic clamp <math>\geq 75</math>th percentile of all obese participants</li> <li>• BMI <math>&gt; 30</math></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• Not obese (BMI <math>&lt; 27</math> kg/m<sup>2</sup>)</li> </ul>
Stefan [26]	<ul style="list-style-type: none"> <li>• IS by OGTT <math>\geq 75</math>th percentile of all obese participants</li> <li>• BMI <math>\geq 30</math></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• IS, normal weight (BMI <math>&lt; 25</math> kg/m<sup>2</sup>)</li> </ul>
Irace [29]	<ul style="list-style-type: none"> <li>• <math>&lt; 3</math> MetS criteria</li> <li>• BMI <math>&gt; 29.9</math></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• <math>&lt; 3</math> MetS, normal weight (BMI 18.5-25 kg/m<sup>2</sup>)</li> </ul>
Khan [27]	<ul style="list-style-type: none"> <li>• <math>&lt; 3</math> MetS<sup>A</sup> Criteria (including CRP <math>\geq 3.0</math> mg/L)</li> <li>• BMI <math>\geq 25</math></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• <math>&lt; 3</math> MetS<sup>A</sup> criteria, normal weight (BMI <math>&lt; 25</math> kg/m<sup>2</sup>)</li> </ul>
Park [28]	<ul style="list-style-type: none"> <li>• 0 MetS<sup>B</sup> criteria</li> <li>• BMI <math>\geq 25</math></li> <li>• Diabetics included</li> </ul>	<ul style="list-style-type: none"> <li>• 0 MetS<sup>B</sup> criteria, normal weight (BMI <math>&lt; 23</math> kg/m<sup>2</sup>)</li> </ul>

<sup>A</sup>Waist circumference excluded, added CRP  $\geq 3.0$  mg/L; <sup>B</sup>Waist circumference  $\geq 90$  cm for men and  $\geq 80$  cm for women, fasting glucose at least 100 mg/dL.

lower than metabolically unhealthy obese participants [26]. Finally, one study also examined multiple measures of cardiovascular changes including left ventricular mass index (LVMI), mitral E/A ratio, E/Ea ratio, TDI and Ea velocity [28]. Park et al. found the MHO had significantly increased LVMI and decreased mitral E/A ratio as compared to the metabolically normal, normal weight participants; indicating changes in heart structure and function in this group [28].

### iii. Other considerations

- a. *Inflammation.* CRP was measured in two studies [27,28] neither of which reported the association of CRP and CVD outcomes in the context of metabolic health and obesity. Khan et al. included vascular inflammation (VI) in the definition of metabolic syndrome [27]. Park adjusted for VI in predicting subclinical CVD outcomes studied [28].

## Discussion

The purpose of the present study was to review the literature that has examined the relationship between the metabolically healthy obese phenotype and cardiovascular disease. The most common definition of MHO used was having a BMI  $\geq 30$  kg/m<sup>2</sup> and less than 3 MetS criteria (8 studies). Nine studies also included insulin sensitivity in the definition of MHO. The most commonly used comparison group was MHNW defined as having a BMI  $< 25$  kg/m<sup>2</sup> and meeting  $< 3$  MetS criteria (9 studies). Of the fourteen studies identified examining CVD

outcomes or all-cause mortality, most were not able to demonstrate a significant association between MHO and increased risk of CVD and mortality. However, a trend towards a slight increase in risk in all but one study was observed, which was supported by increased subclinical disease burden observed in the cross-sectional studies. In the six studies measuring subclinical CVD, the MHO phenotype was associated with increased subclinical CVD burden in four, and this association achieved statistical significance. It appears that MHO individuals have a slightly increased CVD risk as compared to their normal weight counterparts, but the results are mixed as can be seen from the studies reviewed here. It is difficult to determine whether the mixed findings are a result of methodological issues (such as variable follow-up duration, small sample size, non-standardized comparison groups, outcome measurement, etc.) or due to a truly weak effect. Therefore, there is a pressing need for establishing a streamlined, central definition of “metabolically healthy obese” in future studies.

### Defining “metabolically healthy obese”

As mentioned previously, the definitions of MHO are quite heterogeneous and make quantitative synthesis of the reviewed studies difficult. One of the first to identify and review this phenotype in 2001, was Sims [30], who highlighted visceral adiposity and insulin resistance as key determinants of MHO. In the literature analyzed for this review, the most commonly applied definition was the absence or presence of MetS in conjunction with obesity (measured via BMI). IR was often ignored and replaced with fasting glucose. BMI, though a useful tool for

**Table 4 Results; Cross Sectional Studies**

Study	Subjects (Age, Male)	Outcome	Results
Marini [25]	N = 153 MHO = NR (35, 0%) MHNW = 73 (34, 0%)	CCA-IMT	Mean CCA-IMT: MHO = 0.79 (0.08) vs. MHNW = 0.61 (0.11) <b>p &lt; 0.001</b>
Stefan [26]	N = 314 MHO = 31 (47, 39%) MHNW = 54 (45, 17%)	CCA-IMT	Mean CCA-IMT: MHO = 0.54 (0.02) vs. MHNW = 0.51 (0.02) p = NS
Irace [29]	N = 1842 (30–80 years old, 55%) MHO = NR MHNW = NR	CCA-IMT	Mean CCA-IMT: MHO = NR vs. MHNW = NR • Adjusted <sup>A</sup> OR of CCA-IMT MetS: 1.42 (1.10-1.83) <b>p = 0.01</b> BMI: p = NS
Khan [27]	N = 475 MHO = 260 (51, 0%) MHNW = 145 (51, 0%)	CCA-IMT	Mean CCA-IMT: MHO = 0.68 (0.09) vs. MHNW = 0.64 (0.08) <b>p &lt; 0.001</b>
		aPWV	Mean aPWV: MHO = 809.9 (182.3) vs. MHNW = 731 (176.4) <b>p &lt; 0.001</b>
		CAC	Frequency (%) with increased CAC: MHO = 53 (20%) vs. MHNW = 13 (9%) <b>p &lt; 0.001</b>
		AC	Frequency (%) with increased AC: MHO = 130 (50%) vs. MHNW = 47 (32%) <b>p &lt; 0.001</b> • Adjusted <sup>B</sup> OR's of CAC and AC associated with MHO vs. MHNW CAC: 2.38 (1.20,4.70) <b>p = 0.01</b> ; AC: 2.37 (1.49,3.80) <b>p &lt; 0.001</b> • Adjusted <sup>B</sup> regression coefficients associated with MHO vs. MHNW CCA-IMT: 0.034 <b>p &lt; 0.001</b> ; aPWV: 59.7 <b>p = 0.001</b>
Park [28]	N = 2540 MHO = 71 (52, 45%) MHNW = 286 (52, 52%)	CCA-IMT	Mean CCA-IMT: MHO = 0.72 (0.06) vs. MHNW = 0.70 (0.06) p = NS
		aPWV	Mean aPWV: MHO = 12.8 (1.1) vs. MHNW = 12.9 (1.6) p = NS
		LVMi	Mean LVMi: MHO = 42.4 (7.4) vs. MHNW = 35.4 (6.6) <b>p &lt; 0.01</b>
		E/A ratio	Mean E/A ratio: MHO = 1.17 (0.34) vs. MHNW = 1.34 (0.41) <b>p &lt; 0.05</b>

<sup>A</sup>Adjusted for age, sex, smoking, metabolic syndrome, BMI, LDL; <sup>B</sup>Adjusted for age, site of recruitment, education, race, smoking; <sup>C</sup>Adjusted for age, sex, heart rate, CRP, medication for hypertension, treatment for diabetes mellitus.

estimating body fatness, has limitations in that it does not discriminate between lean muscle and fat, or fat distribution. Waist circumference, however, provides an estimate of visceral adiposity which many studies have shown to be significantly associated with IR, type 2 diabetes, and cardiovascular events [31]. Fasting glucose, used in the diagnosis of MetS, has limitations in that it only provides a snap-shot of glucose regulation [32]. Ideally, IR should be measured using the gold standard diagnostic test, the hyperinsulinemic euglycemic glucose clamp (HEGC) [33]. However, this procedure is costly, labor intensive for the investigator, and largely uncomfortable for the patient. Less invasive, but still labor intensive tests such as HOMA-IR or the quantitative insulin sensitivity check index (QUICKI) have been shown to produce similar results and may be useful substitutes for HEGC.

Two often-discussed points in MHO are inflammation as measured by C-reactive protein (CRP) and fatty liver or non-alcoholic fatty liver disease (NAFLD). Inflammation has been shown to promote IR [34]. CRP is thought to be the best biomarker of vascular inflammation and has been shown to be predictive of CVD events [34,35]. In the studies reviewed here, 4 studies included CRP in the definition of MHO, but none of them assessed the relationship of VI and CVD risk. Therefore, the usefulness

of CRP as part of the definition of MHO, or as a predictor of CVD events in the metabolically healthy obese remains uncertain in the studies reviewed here. It is difficult to draw conclusions regarding the usefulness of including VI in the definition of metabolic health or its role as a predictor of CVD from the studies included in this review. Absence of NAFLD has also been explored as a potential identifier of MHO. Fatty liver has been implicated as contributing to IR, and has been associated with increased risk of incident cardiovascular disease even when controlling for metabolic syndrome and obesity [36,37]. Messier et al. found that the MHO had lower liver fat content than their “at-risk” obese equivalents [38]. One study reviewed examined fatty liver in the MHO and found them to have a prevalence of NAFLD similar to overweight participants and greater than those in the normal weight category [26]. Going forward, liver fat could prove a useful tool to diagnose and assess metabolic health of the obese, especially when other metabolic abnormalities are absent. NAFLD can be assessed non-invasively using ultrasound, and provides an early diagnostic marker for cardiovascular disease risk. More long-term studies are needed to confirm its usefulness in the MHO population.

Future studies would be well served to use an increasingly strict definition of MHO which requires measures of

the most significant features (visceral adiposity and IR) while still including information on blood pressure, fasting glucose, cholesterol, triglycerides, liver fat, and inflammation. To show a greater difference in risk, defining MHO as having none of the components may have greater utility. St-Pierre et al. found the relative risk of ischemic heart disease increased linearly with increasing number of metabolic abnormalities [17]. No study reviewed used 0 MetS components to define MHO. However, among the three cohort studies which used  $\leq 1$  MetS criteria in the definition of MHO, only one showed statistically significant difference in the MHO as compared to MHNW [13].

Equally important as defining MHO is the need to determine appropriate comparison groups. In this review, we chose to look at only the comparison between MHO and the “healthiest” group. This was defined as the metabolically healthy, normal weight participants (BMI  $< 25$  kg/m<sup>2</sup>) in most studies; however, some studies chose to use only normal weight individuals with no report of metabolic health, or included overweight individuals in the comparison group. Using these parameters, “unhealthy” traits may have leaked into the “healthiest” groups, leading to crossover bias in analysis which would make true differences between these groups more difficult to detect. No study has compared CVD risks in the MHO by class of obesity. Soverini et al. examined the prevalence of metabolic syndrome and insulin resistance in morbidly obese patients, and found a small percentage maintained insulin sensitivity even at BMI  $> 40$  kg/m<sup>2</sup> [39]. When comparing MHO to the healthiest, the sickest, or even an intermediary (metabolically unhealthy and normal weight), this review stresses the importance of a well defined comparison group in order to make inferences relevant to the general population.

#### **Subclinical disease measures**

When assessing intermediate risk populations such as the obese, the usefulness of traditional risk factor assessment (such as Framingham) diminishes. Measures of subclinical disease are increasingly important as they provide a view of actual disease progression and more accurate event prediction than traditional CVD risk factors. The most common subclinical disease measures used are CCA-IMT, CAC, ankle-brachial index (ABI), and endothelial function. CCA-IMT was the most commonly studied measure of subclinical disease in the studies reviewed. A majority of the studies documented a significant trend towards increased IMT in MHO versus controls. The rising gold standard for measuring degree of atherosclerosis is CAC. Only one study in our analysis measured CAC and found it was significantly increased in the MHO. No study to date has examined whether the differences in outcome (incident CVD and CVD mortality) can be explained by differences in subclinical CVD. In the studies which

examined subclinical disease, all except one were cross-sectional in design, which gives us a snapshot of subclinical disease in the MHO, but does not allow us to examine the progression of disease. The prospective study by Bobbioni-Harsh et al. gave important insights into the development and progression of subclinical disease among the metabolically healthy obese, showing faster progression of subclinical CVD, independent of metabolic abnormalities [23]. Cohort studies allow us to see the time sensitive component of obesity, and the progressive development of cardiovascular risk factors. Future follow-up studies are needed which include multiple measures of subclinical CVD at baseline and follow-up and examine MHO in context of increased burden as compared to their normal weight counterparts.

#### **Expanding the subject population**

Cardiovascular disease prevalence, morbidity, and mortality difference are well established across racial/ethnic and socioeconomic lines [40,41]. Surveillance data from NHANES and BRFSS indicate African Americans experience higher death rates due to both heart disease and stroke [40]. Likewise, Hispanics and Non-Hispanic blacks have higher levels of obesity as compared to Non-Hispanic whites [2]. Of the current studies reviewed, all but one assessed CVD risk in the MHO phenotype in participants of mainly Caucasian or European descent. Surveillance data likewise indicates the prevalence of heart disease, hypertension, and stroke in those persons with incomes below the poverty threshold, is significantly greater than those at or above the poverty threshold [41]. We did not identify any study which examined the prevalence of the MHO phenotype in association with CVD risk in the MHO across racial or socioeconomic lines. Thus, there is an urgent need for longitudinal studies with socioeconomically diverse, multi-ethnic populations in order to correctly identify the CVD risk of the MHO group.

#### **Mechanisms of MHO**

Behavioral and lifestyle factors may play a large role in why a subset of the obese do not present with metabolic abnormalities or present them at a slower pace. However, this is a topic which has not been studied at length and presents mixed findings. Seven of the eight studies measuring physical activity found increased activity in the metabolically healthy obese, when compared to the metabolically unhealthy obese. In addition, several studies found that increased physical activity offset the increased risk of CVD in the MHO. This suggests that all studies examining the MHO phenotype should also assess physical activity, as physical activity appears to nullify the effect of MHO on CVD risk. Hankinson et al. found no difference between diet factors, and physical activity reported between MHO and unhealthy obese participants [42].

However, Messier and colleagues found engaging in physical activity increased the odds of presenting with the MHO phenotype among obese participants [38]. A review by Gill found that increasing physical activity reduced IR, a key factor in defining MHO [43]. While most studies measured physical activity by self report, more accurate results are obtained when physical fitness is directly measured. Ortega et al. measured cardio-respiratory fitness by treadmill test and found MHO participants had significantly higher VO<sub>2</sub> max when compared to the metabolically unhealthy obese [16]. Recent research on sedentary behavior, independent of physical activity, has shown that increased sedentary time is associated with increased risk of diabetes, cardiovascular events, and cardiovascular as well as all-cause mortality [44]. This is in agreement with the belief that the natural tendency of the MHO is to progress to MUHO when physical activity is stopped or reduced [45]. To date, no study has examined sedentary time in the MHO phenotype.

Future research should also target genetic studies to illuminate why some obese individuals do not develop or experience delayed development of metabolic syndrome. For example, one study in mice found that extremely obese mice with a mutation in the *Brd2* gene are protected from developing type 2 diabetes mellitus [46]. This could provide a clue as to why certain obese individuals do not seem to develop the metabolic abnormalities associated with obesity. However, the search for relevant genes in human models continues. It is likely that a gene-environment interaction is at play, similar to the model suggested for the development of obesity [47]. More follow-up studies are needed to examine the transition between MHO and metabolically unhealthy and obese, and whether genetics and lifestyle factors play a role in both development and reversal of such. Likewise, studies conducted in aging cohorts would give insight into the prevalence of this phenotype in the elderly, clarifying the time-dependent relationship of obesity and metabolic abnormality presentation.

## Conclusion

MHO is an important, emerging phenotype with risks somewhere intermediate between healthy, normal weight and unhealthy, obese individuals. Successful work towards a universally accepted definition of MHO would improve (and simplify) future studies and strengthen inter-study comparisons. Usefulness of a definition inclusive of insulin sensitivity in concert with stricter criteria for metabolic syndrome components should be explored, as well as the potential inclusion of fatty liver. As obesity continues to rise, this phenotype will become increasingly important. Clinicians exercise caution in reassuring patients that the metabolically benign phenotype is safe, as increased risk of cardiovascular events and death remains a possibility based on the limited data reviewed.

## Abbreviations

ABI: Ankle-brachial index; AC: Aortic calcium; aPWV: Aortic pulse wave velocity; BMI: Body mass index; CAC: Coronary artery calcium; CCA-IMT: Common carotid artery intima media thickness; CRP: C-reactive protein; E/A: Early/Late; IR: Insulin resistance; IS: Insulin sensitive; LVMI: Left ventricular mass index; MetS: Metabolic syndrome based on the NCEP ATP III Definition: waist circumference  $\geq 102$  cm (male),  $\geq 88$  cm (female), TG  $\geq 150$  mg/dL or use of lipid lowering medications HDL-C  $< 40$  mg/dL (male)  $< 50$  mg/dL (female) or use of lipid lowering medications, blood pressure  $\geq 130/85$  mmHg or use of antihypertensive medications fasting plasma glucose  $\geq 110$  mg/dl or use of antidiabetic medications; MHNW: Metabolically healthy, normal weight; MHO: Metabolically healthy obese; MUHO: Metabolically unhealthy obese; MUNW: Metabolically unhealthy, normal weight; NAFLD: Non-alcoholic fatty liver disease; NR: Not reported; VI: Vascular inflammation; WBC: White blood cell.

## Competing interests

The authors have no competing interests. Please send reprint requests to Khurramn@baptisthealth.net

## Authors' contributions

LR and EA carried out the literature review and data extraction. LR, WM, MB (Blaha), RD, and AS participated in table construction. LR, AA, TF, and MA drafted the manuscript. RB and MB(Budoff) contributed to subclinical CVD section. MR and TT assisted with discussion section. KN conceived of the manuscript concept and oversaw all aspects of manuscript preparation. All authors read and approved the final manuscript.

## Author details

<sup>1</sup>Center for Prevention and Wellness Research, Baptist Health Medical Group, Michigan Ave Suite 500, Miami Beach, Florida. <sup>2</sup>Baptist Health South Florida, Miami, Florida. <sup>3</sup>Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida. <sup>4</sup>The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland. <sup>5</sup>Lipid Clinic Heart Institute, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil. <sup>6</sup>Department of Cardiology, Faculty of Medical Sciences, State University of Campinas (Unicamp), Campinas, São Paulo, Brazil. <sup>7</sup>King Abdul Aziz Cardiac Center, Riyadh, Saudi Arabia. <sup>8</sup>Brigham and Women's Hospital, Harvard School of Medicine, Boston, Massachusetts, USA. <sup>9</sup>Los Angeles Biomedical Research Institute, Torrance, California, USA. <sup>10</sup>Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida.

Received: 25 June 2013 Accepted: 10 December 2013

Published: 8 January 2014

## References

1. World Health Statistics 2012: *World Health Organization*. 20 Avenue Appia, 1211 Geneva 27, Switzerland: WHO Press; 2012. Retrieved February 12, 2013 from [http://www.who.int/gho/publications/world\\_health\\_statistics/2012/en/](http://www.who.int/gho/publications/world_health_statistics/2012/en/).
2. Ogden CL, Carroll MD, Kit BK, Flegal KM: **Prevalence of obesity in the United States, 2009–2010.** *NCHS data brief* 2012, **82**:1–8.
3. Solomon CG, Manson JE: **Obesity and mortality: a review of the epidemiologic data.** *Am J Clin Nutr* 1997, **66**(4 Suppl):1044S–1050S.
4. Flegal KM, Kit BK, Orpana H, Graubard BI: **Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.** *JAMA* 2013, **309**(1):71–82.
5. Finkelstein EA, Trogon JG, Cohen JW, Dietz W: **Annual medical spending attributable to obesity: payer- and service-specific estimates.** *Health Aff (Millwood)* 2009, **28**(5):w822–w831.
6. Blüher M: **The distinction of metabolically 'healthy' from 'unhealthy' obese individuals.** *Curr Opin Lipidol* 2010, **21**(1):38–43.
7. Karelis AD: **To be obese—does it matter if you are metabolically healthy?** *Nat Rev Endocrinol* 2011, **7**(12):699–700.
8. Wildman RP, Muntner P, Reynolds K, et al: **The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the us population (nhanes 1999–2004).** *Arch Intern Med* 2008, **168**(15):1617–1624.

9. Arnlov J, Ingelsson E, Sundstrom J, Lind L: **Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men.** *Circulation* 2010, **121**(2):230–236.
10. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, Mannino S, Crosignani P, Bosi E, Luzi L, et al: **Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study.** *Diabetes Care* 2011, **34**(1):210–215.
11. Hamer M, Stamatakis E: **Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality.** *J Clin Endocrinol Metab* 2012, **97**(7):2482–2488.
12. Hosseinihanah F, Barzin M, Sheikholeslami F, Azizi F: **Effect of different obesity phenotypes on cardiovascular events in Tehran Lipid and Glucose Study (TLGS).** *Am J Cardiol* 2011, **107**(3):412–416.
13. Kuk JL, Ardern CI: **Are metabolically normal but obese individuals at lower risk for all-cause mortality?** *Diabetes Care* 2009, **32**(12):2297–2299.
14. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB: **Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease.** *J Clin Endocrinol Metab* 2006, **91**(8):2906–2912.
15. Ogorodnikova AD, Kim M, McGinn AP, Muntner P, Khan U, Wildman RP: **Incident cardiovascular disease events in metabolically benign obese individuals.** *Obesity (Silver Spring)* 2012, **20**(3):651–659.
16. Ortega FB, Lee DC, Katzmarzyk PT, Ruiz JR, Sui X, Church TS, Blair SN: **The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness.** *Eur Heart J* 2013, **34**(5):389–397.
17. St-Pierre AC, Cantin B, Mauriege P, Bergeron J, Dagenais GR, Despres JP, Lamarche B: **Insulin resistance syndrome, body mass index and the risk of ischemic heart disease.** *CMAJ* 2005, **172**(10):1301–1305.
18. Voulgaris C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C: **Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals.** *J Am Coll Cardiol* 2011, **58**(13):1343–1350.
19. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN: **Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness.** *Diabetes Care* 2005, **28**(2):391–397.
20. Daly CA, Hildebrandt P, Bertrand M, Ferrari R, Remme W, Simoons M, Fox KM: **Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial.** *Heart* 2007, **93**(11):1406–1411.
21. Song Y, Manson JE, Meigs JB, Ridker PM, Buring JE, Liu S: **Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women.** *Am J Cardiol* 2007, **100**(11):1654–1658.
22. Bo S, Musso G, Gambino R, Villosi P, Gentile L, Durazzo M, Cavallo-Perin P, Cassader M: **Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort.** *Am J Clin Nutr* 2012, **96**(5):962–969.
23. Bobbioni-Harsch E, Pataky Z, Makoundou V, Laville M, Disse E, Anderwald C, Konrad T, Golay A: **From metabolic normality to cardiometabolic risk factors in subjects with obesity.** *Obesity (Silver Spring)* 2012, **20**(10):2063–2069.
24. Alam I, Ng TP, Larbi A: **Does inflammation determine whether obesity is metabolically healthy or unhealthy?** *Aging Perspect Mediat Inflamm* 2012, **2012**:14.
25. Marini MA, Succurro E, Frontoni S, Hribal ML, Andreozzi F, Lauro R, Perticone F, Sesti G: **Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women.** *Diabetes Care* 2007, **30**(8):2145–2147.
26. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU: **Identification and characterization of metabolically benign obesity in humans.** *Arch Intern Med* 2008, **168**(15):1609–1616.
27. Khan UI, Wang D, Thurston RC, Sowers M, Sutton-Tyrrell K, Matthews KA, Barinas-Mitchell E, Wildman RP: **Burden of subclinical cardiovascular disease in "metabolically benign" and "at-risk" overweight and obese women: the Study of Women's Health Across the Nation (SWAN).** *Atherosclerosis* 2011, **217**(1):179–186.
28. Park J, Kim SH, Cho GY, Baik I, Kim NH, Lim HE, Kim EJ, Park CG, Lim SY, Kim YH, et al: **Obesity phenotype and cardiovascular changes.** *J Hypertens* 2011, **29**(9):1765–1772.
29. Irace C, Scavelli F, Carallo C, Serra R, Cortese C, Gnasso A: **Body mass index, metabolic syndrome and carotid atherosclerosis.** *Coron Artery Dis* 2009, **20**(2):94–99.
30. Sims EA: **Are there persons who are obese, but metabolically healthy?** *Metabolism* 2001, **50**(12):1499–1504.
31. Lebovitz HE, Banerji MA: **Point: visceral adiposity is causally related to insulin resistance.** *Diabetes Care* 2005, **28**(9):2322–2325.
32. Bonora E, Tuomilehto J: **The pros and cons of diagnosing diabetes with A1C.** *Diabetes Care* 2011, **34**(Suppl 2):S184–S190.
33. Muniyappa R, Lee S, Chen H, Quon MJ: **Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.** *Am J Physiol Endocrinol Metab* 2008, **294**(1):E15–E26.
34. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: **Recent advances in the relationship between obesity, inflammation, and insulin resistance.** *Eur Cytokine Netw* 2006, **17**(1):4–12.
35. Nordestgaard BG, Zacho J: **Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?** *Nutr Metab Cardiovasc Dis* 2009, **19**(8):521–524.
36. Moore JB: **Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.** *Proc Nutr Soc* 2010, **69**(2):211–220.
37. Targher G, Day CP, Bonora E: **Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.** *N Engl J Med* 2010, **363**(14):1341–1350.
38. Messier V, Karelis AD, Robillard ME, Bellefeuille P, Brochu M, Lavoie JM, Rabasa-Lhoret R: **Metabolically healthy but obese individuals: relationship with hepatic enzymes.** *Metabolism* 2010, **59**(1):20–24.
39. Soverini V, Moscatello S, Villanova N, Ragni E, Di Domizio S, Marchesini G: **Metabolic syndrome and insulin resistance in subjects with morbid obesity.** *Obes Surg* 2010, **20**(3):295–301.
40. Romero CX, Romero TE, Shlay JC, Ogden LG, Dabelea D: **Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults.** *Adv Prev Med* 2012, **2012**:172423.
41. Mensah GA, Mokdad AH, Ford ES, Greenland KJ, Croft JB: **State of disparities in cardiovascular health in the United States.** *Circulation* 2005, **111**(10):1233–1241.
42. Hankinson AL, Daviglius ML, Van Horn L, Chan Q, Brown I, Holmes E, Elliott P, Stamler J: **Diet composition and activity level of at risk and metabolically healthy obese American adults.** *Obesity (Silver Spring)* 2012, **21**(3):637–643.
43. Gill JM, Malkova D: **Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity.** *Clin Sci (Lond)* 2006, **110**(4):409–425.
44. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, Khunti K, Yates T, Biddle SJ: **Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis.** *Diabetologia* 2012, **55**(11):2895–2905.
45. Nesto RW: **Obesity: a major component of the metabolic syndrome.** *Texas Heart Institute journal / from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital* 2005, **32**(3):387–389.
46. Wang F, Deeney JT, Denis GV: **Brd2 Gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes.** *Vitam Horm* 2013, **91**:49–75.
47. Speakman JR: **Obesity: the integrated roles of environment and genetics.** *J Nutr* 2004, **134**(8 Suppl):2090S–2105S.

doi:10.1186/1471-2458-14-14

**Cite this article as:** Roberson et al.: Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. *BMC Public Health* 2014 **14**:14.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

